A clinical reference, drawn from 120+ peer-reviewed studies, on how Authentic Dezawa MuseCells® differ from conventional mesenchymal stem cells across safety, mechanism, and delivery.
Muse cells — Multilineage-differentiating Stress-Enduring cells — are naturally occurring, non-tumorigenic, pluripotent-like stem cells found in the connective tissue throughout the body. Discovered in 2010 by Prof. Mari Dezawa at Tohoku University, they travel through the bloodstream to sites of injury, home in on damaged tissue, and differentiate into the specialized cells needed to repair it — all under a natural immune-privilege and non-tumorigenic safety profile that ordinary mesenchymal stem cells (MSCs) do not share. How Dezawa MuseCells® differ from conventional MSCs →
Every Dezawa Muse Signaling™ product begins with the same defined, SSEA-3-positive MuseCell® source — because a signal is only as trustworthy as the cell it comes from. That single authenticated origin is expressed three ways.
The living, reparative cell — immune-privileged and non-tumorigenic, administered through authorized clinicians. The subject of this page.
The concentrated factors MuseCells® release — the signal without the cell, for topical, cosmetic use.
Learn more The vehicleShelf-stable exosomes for skin regeneration and post-procedure repair — topical cosmetic use.
Learn moreDezawa MuseCells® carry a naturally immune-privileged profile — allowing for allogenic (donor-based) administration without triggering rejection or requiring immunosuppressive drugs.
| Immune Marker | Mechanism |
|---|---|
| HLA-G+ | Inhibits natural killer (NK) cells and cytotoxic T-cells, mimicking immune tolerance seen during pregnancy. |
| IDO+ | Converts tryptophan into kynurenine, which inhibits T-cell activation and dampens immune response at inflammation sites. |
| HLA-DR− | Absence of this antigen prevents activation of helper T-cells, reducing the risk of adaptive immune targeting. |
|
1 immune privilege: PMID 36339573 Kuroda 2022 — Endogenous reparative pluripotent Muse cells with a unique immune privilege system · PMID 38560897 Minatoguchi 2024 — Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatment | |
Four safety attributes that distinguish Dezawa MuseCells® from conventional cell therapies — each backed by published evidence.
| Safety Attribute | Dezawa MuseCells® |
|---|---|
| Tumor formation | None observed in vivo + preclinical2 |
| HLA matching required | No3 |
| Immunosuppression | Not required in any human trial3 |
| Pluripotency method | Natural (no reprogramming)4 |
| Allogeneic immunogenicity | Broader MSC field: ~15% of MSC patients in DSA-measurement studies developed donor-specific antibodies.5 Muse cells: HLA-G+ immune privilege — no DSA correlation with safety outcomes. |
|
2 nontumorigenicity: PMID 29041955 PMID 33924240 PMID 38261036 PMID 20421459 PMID 24471964 3 HLA matching / no immunosuppression: PMID 33924240 4 natural pluripotent-like: PMID 21628574 PMID 36241699 5 broader-field MSC immunogenicity: PMC8269175 (PMID 34279481) Sanabria-de la Torre 2021 — Alloreactive Immune Response Associated to Human Mesenchymal Stromal Cells Treatment: A Systematic Review | |
Five characteristics that distinguish this cell line in published literature.
Pluripotency. Dezawa MuseCells® spontaneously differentiate into ectoderm, mesoderm, and endoderm lineages in vivo.
Non-tumorigenic. They do not form teratoma — even in long-term immunodeficient mouse models.
Stress-enduring. They survive harsh environments (hypoxia, serum deprivation) that other stem cells cannot.
Immune tolerance. HLA-G+, IDO+, HLA-DR− profile enables allogenic use without immunosuppressants.
Stable karyotype. Dezawa MuseCells® maintain chromosomal integrity and low telomerase, minimizing mutation risk.
Backed by 120+ global publications — one of the strongest evidence bases in regenerative medicine.
Dezawa MuseCells® and Dezawa MuseExosomes® have been studied primarily in Japan and, in published research, have demonstrated advantages over traditional MSCs across pluripotency, stress resistance, and safety.
Naturally pluripotent. Stress-enduring. IV-delivered to target organs.
Multipotent. Limited differentiation. Local injection; lung-clearance on IV.
Tags: CLIN published clinical · PREP active or in preparation · PRE preclinical · EXP exploratory
Neurology
CNS · motor neuron · perinatal
Cardiovascular
AMI · cardiometabolic
Skin & Wound Healing
EB · cornea · scarring
Orthopedics
SCI · joint · cartilage
Renal
CKD · FSGS · glomerular
Hepatic
regeneration · fibrosis
Pulmonary
IR injury · ARDS
Aesthetics
facial · split-face · skin
Longevity & Healthspan
aging · frailty · performance
Autoimmune & Immune Privilege
mechanism · inflammation
Translational & Multi-indication
cross-border · multi-program
Future Research Directions
additional indications
Claims are based on published studies of Dezawa MuseCells® produced using the licensed intellectual property and exact methodologies of MuseCell Innovations®. Only Dezawa MuseCells® originating from MCI's manufacturing ecosystem and distributed through MCI-designated, licensed partners have the safety and clinical characteristics reported in the research.